Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Supreme Court to Determine Interpretation of Use Code Counterclaims
On Dec. 5, 2011, the Supreme Court heard oral arguments in Caraco Pharmaceutical Labs. v. Novo Nordisk A/S, No. 10-844. The Federal Circuit previously held that Caraco's counterclaim under 21 U.S.C. ' 355(j)(5)(C)(ii) that requested an order requiring Novo to change the allegedly overbroad use code for the patent-in-suit was improper. Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd., No. 2010-1001 (Fed. Cir. 2010). The Federal Circuit held that because the use code contains “an approved method of using the drug” covered by the patent-in-suit, the counterclaim seeking a change of the use code was improper.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.